as much as *some* will try to muddy the water *here* .. ;)

New Post Public Reply Private Reply Replies (0) Message Board
4kids Kelt #56224
483
as much as *some* will try to muddy the water *here* ..

IPIX saw volume in the first 8 months of 2018 @ 33,969,148

IPIX saw volume in the last 4 months of 2018 @ 54,830,246

remember all the *conditioning* NR did *here* and *there* to try and get
actual investors (vs those who play them on various SMBs) to believe X Y and Z
were all selling IPIX

it was total BS ..

again there is the Float which is what is freely traded .. NR via their *efforts* always CONflate the I/O with the Float

Restricted shares are almost always held by the TA in cert form (meaning no
access to by those who collude in illegally manipulating IPIX)

one takes the restricted tally from the I/O total .. and derives the Float on IPIX

OTC Markets (that 4 profit site with all that that implies) clearly interacts with the TA
to update via the security tab .. for those wishing to take notes of what changes and when it changes .. and it's been beyond revealing for what NR did in the last 4 months of 2018

that is why with that bizarre (but not surprising) effort by NR
to *inject* volume into IPIX (and reset the 52 week low @ 7c on 12.31.18)
those who aren't CONned by NR or trading crews .. recognized the *volume injection*
underway since 9.12.18 .. never passed any smell test .. it wasn't the company
it was NR .. and it was done as i noted here back last September .. because NR almost had no choice

NR can't have *crews* hawking *sells* via SMBs .. sans *volume*

and not to put too fine a point on it .. everyone with interest can *grasp* the basics
of IPIX's YTD *volume* @ the EO August 2017 .. running 10M~11M~ higher than
@ the EO August 2018 .. in spite of NRs' *efforts* on IPIX's PPS (2017 part of NRs' 70c stall after name/ticker/cusip change out in June 2017)

08/31/2017 0.71 0.72 0.7048 0.705 140,531
08/31/2018 0.418 0.418 0.39 0.398 142,499


but the issue then becomes with 2/3rds of the volume injected in
the last 4 months of 2018 .. basically bogus
what is NR to do if their resetting rounds fail to part actual investors
from their shares of IPIX of any significance

investors invest .. traders trade .. NR & crews manipulate

remember too for years .. NRs' *relentless PPS compression* has squeezed out most retail traders ..

because unless aligned with a trading crew .. most don't have access to MM (for colluding) .. let alone the capacity to *short* (legally) an OTC target

so a *stuck* NR .. significantly upside down .. failing to part actual investors from
their shares .. throwing everything at them via brand new *decoys for hire* .. has
very few options to play when their playbook is *known*

curious to see what mgmt files next ..

4kids
Quote:

For some odd reason,it seems to me that Leo doesn't want to sell shares to Aspire just to see them immediately turn around and dump them into the hands of NR to be used against IPIX.

So now it seems that the "swamp creatures" want exactly that to happen.

Kelt













Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating the Nitty-Gritty of Cabin Rental Management

Updated Category News Views 10

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Continue Reading
D2L Ventures into Vietnam with Van Lang Alliance

Updated Category News Views 16

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Continue Reading
Navigating AI Laws: A New Era for Privacy & Security

Updated Category News Views 16

Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...

Continue Reading
First Student Reduces Collisions by 63% with HALO Tech

Updated Category News Views 13

Making Every School Bus Ride Safer Here's some good news in the world of transportation, especially if you're keen on keeping kids safe on the daily school bus run. First Student's HALO™ Connected Transportation Platform claims it made a significant dent in reducing accidents—specifically, a 63% cut in forward collision risk. It's a big promise when you're talking...

Continue Reading
Alaska LNG Project Boosted by Strategic Positioning

Updated Category News Views 10

Alaska LNG: Right Place, Right Time Someone bring out the confetti, because Paul Sullivan, Co-Chairman of Gastech, is celebrating Alaska LNG like it's 1999. And for good reason. If Alaska ever played its cards right, now's the moment according to the industry veteran. After Gastech 2026 wrapped its events in Bangkok last month, Sullivan laid out why the stars are aligning...

Continue Reading
DOCS Faces Investor Legal Battle for Alleged Misconduct

Updated Category News Views 11

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...

Continue Reading
INSPIRE 2026: Luxury Hotel Trends and Investments

Updated Category News Views 5

Luxury Hotels: Where's the Money Headed? All eyes on Orlando this December 15–16, where the International Luxury Hotel Association (ILHA) is calling the shots. INSPIRE 2026 is the marquee event of the year for luxury hospitality, and it ain't just about starry chandeliers and velvet drapes. We're talking real capital shifts, margins pinching tighter, and a future...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 6

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
OppFi Readies Q3 Earnings; Investors Eye Financials

Updated Category News Views 8

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Continue Reading
Senté’s Heparan Sulfate Pairing: Peer-Reviewed Success

Updated Category News Views 8

Senté's Science-Driven Approach in Skincare Alright, cutting through the skincare noise, Senté Labs has pulled off something impressive—not just another jar of promises but actual, peer-reviewed science backing their Defense C Serum. Published in the Journal of Cosmetic Dermatology, this study isn't just talk about ingredients; it's a show of real results. This isn't...

Continue Reading

Top 5 Most Recently Viewed Articles

Ontex's Q3 Results Show Strong Progress Despite Market Challenges

Updated Category News Views 143

Ontex's Financial Performance for Q3 Ontex has released its latest financial results, revealing a noteworthy overall performance in the third quarter. Despite facing some challenges in consumer demand, the company reported a revenue of €445 million, marking a 3.8% year-on-year decrease when compared to comparable periods. However, when assessed against the previous...

Continue Reading
Youth Financial Independence: The Case for 16-Year-Old ISAs

Updated Category News Views 145

Empowering Youth to Manage Their Finances The conversation around financial independence for the younger generation is gaining traction. A recent campaign is advocating that the Government lowers the age for opening Individual Savings Accounts (ISAs) to 16 years old. This proposal aligns with various rights already held by young people, such as leaving school, working...

Continue Reading
Gantry Achieves Milestone with $20 Billion Loan Servicing Growth

Updated Category News Views 104

Gantry Sees Significant Increase in Q3 Loan Production Gantry, known as the largest independent commercial mortgage banking firm in the U.S., has reported impressive growth in new commercial mortgage production for the third quarter. The quarter saw a notable increase of nearly 10% over the totals from both the previous two quarters. This positive trend is bolstered by...

Continue Reading
Icahn Enterprises L.P. to Host Q3 2025 Earnings Call Discussion

Updated Category News Views 144

Upcoming Earnings Conference Call for Icahn Enterprises L.P. Icahn Enterprises L.P. (NASDAQ: IEP) has exciting news to share regarding its upcoming Q3 2025 earnings conference call. This important event will take place on a webcast, scheduled for Wednesday, November 5, 2025, at 10:00 a.m. Eastern Time. Investors and interested parties are encouraged to tune in to hear the...

Continue Reading
Iovance Biotherapeutics Announces Conference Presentations in 2025

Updated Category News Views 697

Iovance Biotherapeutics Announces Upcoming Conference Appearances Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering biotechnology firm dedicated to advancing treatments through innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies, has revealed that its senior executive team will be showcasing their expertise at several prestigious conferences in...

Continue Reading